|
Variable
|
All patients N = 1221
|
Patients without CTCs N = 970
|
Patients with CTCs N = 251
|
p-valuea
|
|---|
|
Age (years)
| | | |
0.41b
|
|
Median
|
53.0
|
53.0
|
54.0
| |
|
Range
|
22 - 85
|
22 - 85
|
33 - 75
| |
|
Tumor stage
| | | |
0.34c
|
|
pT1
|
489 (40.0 %)
|
397 (40.9 %)
|
92 (36.7 %)
| |
|
pT2
|
652 (53.4 %)
|
511 (52.7 %)
|
141 (56.2 %)
| |
|
pT3
|
63 (5.2 %)
|
47 (4.8 %)
|
16 (6.4 %)
| |
|
pT4
|
17 (1.4 %)
|
15 (1.5 %)
|
2 (0.8 %)
| |
|
Nodal stage
| | | |
0.23c
|
|
pN0
|
422 (34.6 %)
|
341 (35.2 %)
|
81 (32.3 %)
| |
|
pN1
|
561 (45.9 %)
|
446 (46.0 %)
|
115 (45.8 %)
| |
|
pN2
|
165 (13.5 %)
|
126 (13.0 %)
|
39 (15.5 %)
| |
|
pN3
|
70 (5.7 %)
|
54 (5.6 %)
|
16 (6.4 %)
| |
|
unknown
|
3 (0.2 %)
|
3 (0.3 %)
|
0 (0.0 %)
| |
|
Histological grading
| | | |
0.30c
|
|
G1
|
59 (4.8 %)
|
43 (4.4 %)
|
16 (6.4 %)
| |
|
G2
|
604 (49.5 %)
|
479 (49.4 %)
|
125 (49.8 %)
| |
|
G3
|
557 (45.6 %)
|
447 (46.1 %)
|
110 (43.8 %)
| |
|
unknown
|
1 (0.1 %)
|
1 (0.1 %)
|
0 (0.0 %)
| |
|
Histological type
| | | |
0.26d
|
|
ductal
|
1019 (83.5 %)
|
812 (83.7 %)
|
207 (82.5 %)
| |
|
lobular
|
122 (10.0 %)
|
91 (9.4 %)
|
31 (12.4 %)
| |
|
other
|
80 (6.6 %)
|
67 (6.9 %)
|
13 (5.2 %)
| |
|
Hormone receptor status
| | | |
0.73d
|
|
negative
|
368 (30.1 %)
|
290 (29.9 %)
|
78 (31.1 %)
| |
|
positive
|
851 (69.7 %)
|
678 (69.9 %)
|
173 (68.9 %)
| |
|
unknown
|
2 (0.2 %)
|
2 (0.2 %)
|
0 (0.0 %)
| |
|
HER2 status
| | | |
0.88d
|
|
negative
|
906 (74.2 %)
|
720 (74.2 %)
|
186 (74.1 %)
| |
|
positive
|
296 (24.2 %)
|
234 (24.1 %)
|
62 (24.7 %)
| |
|
unknown
|
19 (1.6 %)
|
16 (1.6 %)
|
3 (1.2 %)
| |
|
Menopausal status
| | | |
0.88d
|
|
premenopausal
|
521 (42.7 %)
|
415 (42.8 %)
|
106 (42.2 %)
| |
|
postmenopausal
|
700 (57.3 %)
|
555 (57.2 %)
|
145 (57.8 %)
| |
|
Type of surgery
| | | |
0.27d
|
|
breast conserving
|
876 (71.7 %)
|
703 (72.5 %)
|
173 (68.9 %)
| |
|
mastectomy
|
345 (28.3 %)
|
267 (27.5 %)
|
78 (31.1 %)
| |
|
Radiotherapy
| | | |
1.00d
|
|
no
|
175 (14.3 %)
|
139 (14.3 %)
|
36 (14.3 %)
| |
|
yes
|
1045 (85.6 %)
|
830 (85.6 %)
|
215 (85.7 %)
| |
|
unknown
|
1 (0.1 %)
|
1 (0.1 %)
|
0 (0.0 %)
| |
|
Endocrine therapy
| | | |
0.81d
|
|
no
|
333 (27.3 %)
|
266 (27.4 %)
|
67 (26.7 %)
| |
|
yes
|
887 (72.6 %)
|
703 (72.5 %)
|
184 (73.3 %)
| |
|
unknown
|
1 (0.1 %)
|
1 (0.1 %)
|
0 (0.0 %)
| |
|
HER2-targeted therapy
| | | |
0.54d
|
|
no
|
965 (79.0 %)
|
770 (79.4 %)
|
195 (77.7 %)
| |
|
yes
|
255 (20.9 %)
|
199 (20.5 %)
|
56 (22.3 %)
| |
|
unknown
|
1 (0.1 %)
|
1 (0.1 %)
|
0 (0.0 %)
| |
-
aAll tests without unknowns
-
bMann–Whitney U test
-
cCochran–Armitage test for trend
-
dChi-square test
